©2022 Stanford Medicine
INCB7839 in Treating Children With Recurrent/Progressive High-Grade Gliomas
Trial ID: NCT04295759
This is a multicenter phase 1 trial of INCB7839 for children with recurrent or progressive high-grade gliomas, including, but not limited to, diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs), after upfront therapy.
A Phase I Study of the Adam-10 Inhibitor, INCB7839 in Children With Recurrent/Progressive High-Grade Gliomas to Target Microenvironmental Neuroligin-3
- Patients with recurrent/progressive high-grade gliomas, as defined by progressive
neurologic abnormalities or worsening neurologic status not explained by causes
unrelated to tumor progression (e.g., anticonvulsant or corticosteroid wean,
electrolyte disturbances, sepsis, hyperglycemia, etc.), OR a ≥ 25% increase in the
bi-dimensional measurement, taking as a reference the smallest disease measurement
recorded since diagnosis utilizing the MRI sequence best demonstrating tumor, OR the
appearance of a new/metastatic tumor lesion(s) since diagnosis.
- Eligible diagnoses include but are not limited to the following: diffuse intrinsic
pontine glioma (DIPG), H3K27M-altered diffuse midline glioma (DMG), glioblastoma
multiforme, anaplastic astrocytoma and anaplastic oligodendroglioma. Spinal cord
tumors are eligible with pathologic confirmation of the above.
- Please note: Patients with a radiographically typical DIPG at diagnosis, defined as a
tumor with a pontine epicenter and diffuse involvement of more than 2/3 of the pons,
are eligible without histologic confirmation.
- Patients with pontine lesions that do not meet these radiographic criteria will be
eligible if there is histologic confirmation of pontine glioma WHO II-IV.
- Patients with diffuse or multi-focal disease are eligible; patients with
leptomeningeal spread are eligible.
- Patients must be ≥ 3 but ≤ 21 years of age at the time of enrollment.
- Patients must have a BSA ≥ 0.70-2.50 m2 for dose 120 mg/m2/dose BID.
- Patients must have a BSA ≥ 0.55-2.80 m2 for dose 80 mg/m2/dose BID (Patients who have
BSA 0.55-1.00 m2 will only receive 100 mg AM dose).
Ability to Swallow
- Patients must be able to swallow tablets whole.
- Patients must have measurable disease in two dimensions on MRI to be eligible.
- Patients must have failed at least 1 standard, tumor-directed treatment besides
surgery and recovered from the acute treatment-related toxicities (defined as < Grade
1) of all prior chemotherapy, immunotherapy, or radiotherapy prior to enrollment on
- Patients must be ≥ 28 days from any prior surgery at the time of study enrollment
(with the exception of minor dental and dermatological procedures).
- Patients must have received their last dose of known myelosuppressive anticancer
therapy at least 21 days prior to enrollment or at least 42 days if nitrosourea.
- Investigational/ Biologic Agent
- Biologic or investigational agent (anti-neoplastic): Patients must have recovered from
any acute toxicity potentially related to the agent and received their last dose of
the investigational or biologic agent ≥ 7 days prior to study enrollment.
- For agents that have known adverse events occurring beyond 7 days after
administration, this period must be extended beyond the time during which adverse
events are known to occur.
- Monoclonal antibody treatment and agents with known prolonged half-lives: Patients
must have recovered from any acute toxicity potentially related to the agent and
received their last dose of the agent ≥ 28 days prior to study enrollment.
- Immunotherapies: Patients who have received checkpoint inhibitors or other
immunotherapies with a known potential for pseudoprogression and who have assumed
tumor progression must be at least 12 weeks from prior immunotherapy AND have at least
two MRI scans at least 4 weeks apart demonstrating further progression OR have a
biopsy to confirm tumor progression OR have new site(s) of disease.
Patients must have had their last fraction of:
- Craniospinal irradiation, whole brain radiation, total body irradiation or radiation
to ≥ 50% of pelvis or spine ≥ 42 days prior to enrollment.
- Focal irradiation ≥ 14 days prior to enrollment.
- Local palliative irradiation to site other than primary tumor progression site ≥ 14
days prior to enrollment.
- Stem Cell Transplant
Patients must be:
- ≥ 6 months since allogeneic stem cell transplant prior to enrollment with no evidence
of active graft vs. host disease.
- ≥ 3 months since autologous stem cell transplant prior to enrollment.
- Patients with neurological deficits should have deficits that are stable for a minimum
of 7 days prior to enrollment.
- Patients with seizure disorders may be enrolled if seizures are well controlled.
- Karnofsky Performance Scale (KPS for > 16 years of age) or Lansky Performance Score
(LPS for ≤ 16 years of age) assessed within two weeks of enrollment must be ≥ 50.
Organ Function: Patients must have adequate organ and marrow function as defined below:
- Absolute neutrophil count ≥ 1.0 x 10^9 cells/ L
- Platelets > 100 x 10^9 cells/ L (unsupported, defined as no platelet transfusion
within 7 days)
- Hemoglobin ≥ 8 g/dL (may receive transfusions)
- Total bilirubin ≤ 1.5 times institutional upper limit of normal (ULN)
- ALT (SGPT) and AST (SGOT) < 3 x institutional upper limit of normal (ULN)
- Albumin ≥ 2 g/dL
- Serum creatinine based on age/gender as noted in institutional normal range. Patients
that are not within institutional normal range but have a 24-hour Creatinine Clearance
or GFR (radioisotope or iothalamate) ≥ 70 mL/min/1.73 m^2 are eligible.
- Patients who are receiving dexamethasone must be on a stable or decreasing dose for at
least 7 days prior to enrollment.
- Patients must be off all colony-forming growth factor(s) for at least 7 days prior to
enrollment (e.g., filgrastim, sargramostim or erythropoietin). Fourteen (14) days must
have elapsed if patient received a long-acting formulation.
- Patients of childbearing or child fathering potential must be willing to use a
medically acceptable form of birth control, which includes abstinence, while being
treated on this study.
- The patient or parent/guardian is able to understand the consent and is willing to
sign a written informed consent document according to institutional guidelines.
HIV Positive Patients
- HIV-positive patients are eligible if the following criteria are met:
- Stable on their antiretroviral agents
- Have CD4 counts above 400/mm^3
- Undetectable viral loads, and
- No need for prophylactic medications for an opportunistic infections
Pregnancy or Breast-feeding
- Pregnant women or nursing mothers are excluded from this study. Female patients of
childbearing potential must have a negative serum or urine pregnancy test within 72
hours prior to receiving the first dose of study medication. If the urine test is
positive or cannot be confirmed as negative, a serum pregnancy test will be required.
- Pregnant or breast-feeding women are excluded from this study due to risks of
fetal and teratogenic adverse events as seen in animal studies.
- Patients with any clinically significant unrelated systemic illness (e.g., serious
infections or significant cardiac, pulmonary, hepatic or other organ dysfunction),
that in the opinion of the investigator would compromise the patient's ability to
tolerate protocol therapy, put them at additional risk for toxicity or would interfere
with the study procedures or results.
- Patients with any other current malignancy.
- Patients with uncontrolled hypertension (i.e., a blood pressure (BP) > 95th percentile
for age, height, and gender; patients with values above these levels must have their
blood pressure controlled with medication prior to starting study drug).
- The normal blood pressure by height, age, and gender tables can be accessed in
the Generic Forms section of the PBTC member's webpage.
- Patients who are ≥ 18 years of age must have blood pressure that is < 140/90 mm
of Hg at the time of registration.
- Patients who are receiving any other anti-cancer, investigational or alternative
(e.g., cannabinoids) drug therapy are ineligible.
- Prisoners will be excluded from this study.
Inability to participate
- Patients who in the opinion of the investigator are unwilling or unable to return for
required follow-up visits or obtain follow-up studies required to assess toxicity to
therapy or to adhere to drug administration plan, other study procedures and study
- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition.
- Patients with a history of allergy to pork products due to contraindications with low
molecular weight heparin (LMWH).
- Patients with a known coagulopathy or bleeding disorder (e.g., von Willebrands
disease) are not eligible.
- Patients with a history of non-central line related thrombosis or disorders that
promote clotting (e.g., anti-thrombin III deficiency, Lupus anticoagulant) are not
- Significant family history of thrombosis (i.e. deep venous thrombosis or pulmonary
embolus) in a first-degree relatives (i.e., parents or siblings) are not eligible.
- Estrogen containing contraceptives are not permitted due to thrombotic risk.
Progestin-only contraception along with alternate forms of contraception are
- Patients should be counseled to avoid smoking/tobacco products.
- If there is any contraindication to DVT prophylaxis, the patient is not eligible.
Family history must be documented to the best extent it is known.
Subjects with current or prior symptomatic intratumoral or intracranial hemorrhage are
Subjects with asymptomatic evidence of new CNS hemorrhage of more than punctate size (i.e.,
≥ 4 mm) and/or more than one punctate focus of hemorrhage (< 4 mm or not seen on more than
one slice) on baseline MRI obtained within 14 days prior to study enrollment are